Evidence map›Paper›PMID 35342696›Full record

Observational studyGlobal heart2022

Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?

Evgeniya V Shalaeva, Alisher К Shadmanov, Feruza L Azizova, Khilola T Mirakhmedova, Franz H Messerli, Oscar H Franco, Hugo Saner

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Global heart, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evgeniya V ShalaevaTashkent Medical Academy, Tashkent, UZ.ORCID 0000-0002-4661-0627
Alisher К ShadmanovTashkent Medical Academy, Tashkent, UZ.ORCID 0000-0002-9594-2214
Feruza L AzizovaTashkent Medical Academy, Tashkent, UZ.ORCID 0000-0001-6360-503X
Khilola T MirakhmedovaTashkent Medical Academy, Tashkent, UZ.ORCID 0000-0003-1025-8825
Franz H MesserliDepartment for Cardiology, University Hospital Bern, Bern, CH.ORCID 0000-0002-4107-2583
Oscar H FrancoInstitute for Social and Preventive Medicine, University of Bern, CH.ORCID 0000-0002-4606-4929
Hugo SanerInstitute for Social and Preventive Medicine, University of Bern, CH.ORCID 0000-0002-8025-7433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with increase mortality or a more severe course of COVID-19, and if treatment and control of hypertension mitigates this risk. Methods: This is a prospective multi-center observational cohort study with 30-day outcomes of 9,531 consecutive SARS-CoV-2 PCR-positive patients ≥ 18 years old (41.9 ± 9.7 years, 49.2% male), Uzbekistan, June 1-September 30, 2020. Patients were subclassified according to JNC8 criteria into six blood pressure stages. Univariable and multiple logistic regression was conducted to examine how variables predict outcomes. Results: The 30-days all-cause mortality was 1.18% (n = 112) in the whole cohort. After adjusting for age, sex, history of myocardial infarction (MI), type-2 diabetes, and obesity, none of six JNC8 groups showed any significant difference in all-cause mortality. However, age was associated with an increased risk of 30-days all-cause mortality (OR = 1.09, 95%CI [1.07-1.12], p < 0.001), obesity (OR = 7.18, 95% CI [4.18-12.44], p < 0.001), diabetes (OR 4.18, 95% CI [2.58-6.76], p < 0.001), and history of MI (OR = 2.68, 95% CI [1.67-4.31], p < 0.001). In the sensitivity test, being ≥ 65 years old increased mortality 10.56-fold (95% CI [5.89-18.92], p < 0.001). Hospital admission was 12.4% (n = 1,183), ICU admission 1.38% (n = 132). The odds of hospitalization increased having stage-2 untreated hypertension (OR = 4.51, 95%CI [3.21-6.32], p < 0.001), stage-1 untreated hypertension (OR = 1.97, 95%CI [1.52-2.56], p < 0.001), and elevated blood pressure (OR = 1.82, 95% CI [1.42-2.34], p < 0.001). Neither stage-1 nor stage-2 treated hypertension patients were at statistically significant increased risk for hospitalization after adjusting for confounders. Presenting with stage-2 untreated hypertension increased the odds of ICU admission (OR = 3.05, 95 %CI [1.57-5.93], p = 0.001). Conclusions: Lone hypertension did not increase COVID-19 mortality or in treated patients risk of hospitalization.

Indexed as

COVID-19HypertensionAdolescentAgedFemaleHumansMaleProspective StudiesRisk FactorsSARS-CoV-2COVID-19HypertensionJNC8 classificationmortalitySARS-CoV-2

Identifiers

PMID35342696
PMCPMC8896243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.